WikiMD logo

COVID-19 portal | Vitamin D | CDC | Vaccine | Ketogenic diet

WikiMD is the world's largest medical encyclopedia with
327,207 articles, 3,627,715 edits, & 32,959,007 views

Let food be thy medicine, and medicine be thy food - Hippocrates


From WikiMD
Jump to navigation Jump to search

Information about Ramucirumab

Ramucirumab is a human monoclonal antibody to the vascular endothelial growth factor (VEGF) receptor 2 and is an antiangiogenesis agent used in the therapy of advanced colorectal, gastric and lung cancers.

Liver safety of Ramucirumab

Ramucirumab has not been linked to serum enzyme elevations during therapy or to instances of idiosyncratic acute liver injury, but has been reported to worsen liver failure in patients with decompensated cirrhosis (Child Class B or C). 

Mechanism of action of Ramucirumab

Ramucirumab (ra" mue sir' ue mab) is a recombinant human monoclonal IgG1 antibody to the vascular endothelial growth factor receptor 2.  Receptors for VEGF are present on endothelial cells, and the engagement of VEGF with these receptors promotes cell proliferation and angiogenesis.  Inhibition of VEGF receptor 2 signaling decreases formation of new blood vessels, which plays an important role in growth and spread of cancer cells.  When used in combination with other antineoplastic agents, ramucirumab has been shown to extend progression-free and overall survival in several forms of advanced cancer. 

FDA approval information for Ramucirumab

Ramucirumab was approved in the United States in 2014 for use in refractory, advanced gastric and metastatic non-small cell lung cancer.  Indications were broadened in 2015 to include metastatic colorectal cancer.  Ramucirumab is available in solution in single use vials of 100 mg in 10 mL or 500 mg in 50 mL (10 mg/mL) under the brand name Cyramza. 

Dosage and administration for Ramucirumab

The typical dose is 8 or 10 mg/kg intravenously at intervals of every 2 or 3 weeks based upon indication the other antineoplastic agents used in combination.  Ramucirumab has significant adverse side effects

Side effects of Ramucirumab

Common adverse events include diarrhea, fatigue, anorexia, epistasis, hypertension, neutropenia, and stomatitis.  Uncommon, but potentially severe adverse events include arterial thromboembolic events, severe hypertension, infusion reactions, impaired wound healing, worsening of cirrhosis, thyroid dysfunction, renal dysfunction including proteinuria and nephrotic syndrome, and embryofetal toxicity.


Cost and Coupons - Ramucirumab

Reviews for Ramucirumab

The article on Ramucirumab is a stub. YOU can help Wikimd by expanding it!

Medication resources

Learn more


WikiMD Resources - Ramucirumab

Help WikiMD:Join WikiMD as an an editor and help improve the page Ramucirumab or others.
W8MD weight loss logo

Ad. Tired of being overweight?. W8MD's insurance Weight loss program can HELP*

Quick links: Medicine Portal | Encyclopedia‏‎‏‎ | Gray's Anatomy‏‎ | Topics‏‎ |‏‎ Diseases‏‎ | Drugs | Wellness | Obesity‏‎ | Metabolic syndrome | Weight loss*
Disclaimer: The entire contents of WIKIMD.ORG are for informational purposes only and do not render medical advice or professional services. If you have a medical emergency, you should CALL 911 immediately! Given the nature of the wiki, the information provided may not be accurate, misleading and or incorrect. Use the information on this wiki at your own risk! See full Disclaimer.
Link to this page: <a href="">Ramucirumab</a>

  • Individual results may vary for weight loss from our sponsors.